Bayer accused of promoting Yaz birth control for unapproved uses

Company faces off-label marketing allegations in lawsuits

For years, Bayer AG has faced lawsuits concerning the safety of its Yaz birth control medication. Now, the German drug company is accused of marketing its oral contraceptives for unapproved uses as well as keeping women in the dark about the drug’s health risks.

According to company emails that were disclosed as part of litigation in which plaintiffs claim that Yaz caused serious health problems, Bayer officials discussed how to promote Yaz as a treatment for all types of premenstrual syndrome (PMS) even though U.S. regulators had only approved the drug to treat the most severe form of PMS. Bayer officials sent salespeople an email saying that they should cite a Woman’s Day magazine article when touting Yaz as a safe PMS treatment.

Regulators have questioned the safety of Bayer’s contraceptives, which contain drospirenone, a synthetic hormone that can alter the body’s normal balance of salt and water and lead to elevated potassium levels that can cause major health issues, such as blood clots, heart attacks and strokes. Lawyers representing the plaintiffs who are suing Bayer claim that the Food and Drug Administration (FDA) reported at least 50 deaths tied to the company’s birth control pills between 2004 and 2008. Bayer faces more than 10,000 lawsuits from plaintiffs who claim the birth control pill caused injuries.

The FDA recently conducted a study revealing that women who took drospirenone-containing pills, including Bayer’s Yaz, were 74 percent more likely to suffer blood clots than women on other low-estrogen contraceptives. The agency has scheduled a hearing for Dec. 8 to further discuss its findings.

Visit Bloomberg for more information about Bayer’s alleged off-label marketing.

Comments

InsideScoop Daily eNewsletter

InsideScoop delivers the latest-breaking news affecting in-house counsel. Get the latest business trends, current corporate litigation, labor developments, technology initiatives and more — FREE. Sign up now!

You have been subscribed! You will receive a confirmation email soon.

See the entire list of InsideCounsel eNewsletters.

Resource Library


13 Things to do Now to Reduce Risk and Avoid...

We have developed best practices for lowering your e-Discovery costs, shortening the length of your...

7 Simple Strategies for Improving Legal Fee Budgeting Certainty

Understanding the legal fee budgeting paradigm and following seven simple strategies will help you control...

Complimentary White Paper: Best Practices for Meeting Critical eDiscovery Challenges

Packed with practical advice, this white paper discusses best practices for meeting eDiscovery challenges across...

Complimentary White Paper "Key Considerations for Collection Methodologies and Resources"

This white paper addresses the need for companies to reevaluate their current collection policies in...

Moving Matters In-House: How Technology Enables Legal In-Sourcing

Strategically shifting more matters to in-house counsel has proven to be an effective strategy to...

5 Ways to Promote Responsible Content Sharing

Find out five ways that organizations can promote responsible sharing of content among employees by...

Reducing the Costs of eDiscovery from Collection to Court!

Predictive coding is only one of many ways organizations can make eDiscovery faster, cheaper and...

Discovery Shifts to the Cloud

Adoption of Cloud computing continues to gain momentum. How can IT and Legal Teams avoid...

Lower Your Total Cost of Ownership

With the deployment of Proofpoint Enterprise Archive, organizations have realized significant cost savings in automating...

Health and Safety Risks of Counterfeits in the Global Supply...

This whitepaper underscores the prevalence of counterfeits within global supply chains across a number of...

View All »

Advertisement. Closing in 15 seconds.